方盛制药：公司将深入推进“自研+引进+混合”的多元研发模式

互动易2025-07-25

有投资者向方盛制药提问，贵司在2024年年报首次提到“创新生物药研发是面向未来的重要布局，尽管会面临诸多挑战，通过借助前沿生物技术，探索疾病治疗的新途径，为集团的长远发展开辟新的增长极”。截至目前，贵司在创新生物药的布局进展如何？后面主要是考虑内生式增长还是并购重组的方式以迅速打开创新生物药的局面？公司回答表示，尊敬的投资者，您好!公司将深入推进“自研+引进+混合”的多元研发模式，在各细分领域...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2554752842?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-25 15:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2554752842","market":"sh","top_or_hot":-1,"title":"方盛制药：公司将深入推进“自研+引进+混合”的多元研发模式","media":"互动易","content":"<div>\n<p>有投资者向方盛制药提问， 贵司在2024年年报首次提到“创新生物药研发是面向未来的重要布局，尽管会面临诸多挑战，通过借助前沿生物技术，探索疾病治疗的新途径，为集团的长远发展开辟新的增长极”。截至目前，贵司在创新生物药的布局进展如何？后面主要是考虑内生式增长还是并购重组的方式以迅速打开创新生物药的局面？公司回答表示，尊敬的投资者，您好!公司将深入推进“自研+引进+混合”的多元研发模式，在各细分领域...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725153635a6c12914&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>方盛制药：公司将深入推进“自研+引进+混合”的多元研发模式</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n方盛制药：公司将深入推进“自研+引进+混合”的多元研发模式\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-25 15:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725153635a6c12914&s=b><strong>互动易</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>有投资者向方盛制药提问， 贵司在2024年年报首次提到“创新生物药研发是面向未来的重要布局，尽管会面临诸多挑战，通过借助前沿生物技术，探索疾病治疗的新途径，为集团的长远发展开辟新的增长极”。截至目前，贵司在创新生物药的布局进展如何？后面主要是考虑内生式增长还是并购重组的方式以迅速打开创新生物药的局面？公司回答表示，尊敬的投资者，您好!公司将深入推进“自研+引进+混合”的多元研发模式，在各细分领域...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725153635a6c12914&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603998","symbol_name":"方盛制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725153635a6c12914&s=b","article_id":"2554752842","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725153635a6c12914&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554752842","pubTimestamp":1753428786,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公司将深入推进“自研+引进+混合”的多元研发模式，在各细分领域全面布局，全力推动公司的创新发展进程；持续发挥“融系”公司的资源整合优势，不断加强研发平台建设，吸引高端人才，全面提升研发效率与创新竞争力，进一步丰富中药创新药、化学仿制药、原料药研发产品管线，为打造具备持续竞争力的产品集群战略布局打下坚实基础。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"603998":"方盛制药","BK0239":"医药制造","BK0060":"抗癌"},"translate_title":"Fangsheng Pharmaceutical: The company will further promote the diversified R&D model of \"self-research + introduction + mixing\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603998":1},"content_text":"有投资者向方盛制药提问， 贵司在2024年年报首次提到“创新生物药研发是面向未来的重要布局，尽管会面临诸多挑战，通过借助前沿生物技术，探索疾病治疗的新途径，为集团的长远发展开辟新的增长极”。截至目前，贵司在创新生物药的布局进展如何？后面主要是考虑内生式增长还是并购重组的方式以迅速打开创新生物药的局面？公司回答表示，尊敬的投资者，您好!公司将深入推进“自研+引进+混合”的多元研发模式，在各细分领域全面布局，全力推动公司的创新发展进程；持续发挥“融系”公司的资源整合优势，不断加强研发平台建设，吸引高端人才，全面提升研发效率与创新竞争力，进一步丰富中药创新药、化学仿制药、原料药研发产品管线，为打造具备持续竞争力的产品集群战略布局打下坚实基础。推动集团在医药创新领域持续前行，实现高质量发展。感谢您对公司的关注!敬请注意投资风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554752842","isCrawlerRequest":true}